amplification activates ERBB3/PI3E/AKT signaling in EGFR mutant lung cancers, and causes resistance to EGFR kinase inhibitors. erlotinib are effective medical therapies for advanced non-small cell lung malignancy (NSCLC) individuals with activating mutations (Asahina et al., 2006; Inoue et al., 2006; Paz-Ares et al., 2006; Sequist et al., 2008; Tamura AT7867 et al., 2008). A recent… Continue reading amplification activates ERBB3/PI3E/AKT signaling in EGFR mutant lung cancers, and causes